Department of Justice February 17, 2009 – Federal Register Recent Federal Regulation Documents

Importer of Controlled Substances; Notice of Registration
Document Number: E9-3396
Type: Notice
Date: 2009-02-17
Agency: Drug Enforcement Administration, Department of Justice
Manufacturer of Controlled Substances; Notice of Registration
Document Number: E9-3393
Type: Notice
Date: 2009-02-17
Agency: Drug Enforcement Administration, Department of Justice
Importer of Controlled Substances; Notice of Registration
Document Number: E9-3392
Type: Notice
Date: 2009-02-17
Agency: Drug Enforcement Administration, Department of Justice
Meeting of the Federal Advisory Committee on Juvenile Justice.
Document Number: E9-3254
Type: Notice
Date: 2009-02-17
Agency: Department of Justice, Office of Justice Programs, Justice Programs Office
The Office of Juvenile Justice and Delinquency Prevention (OJJDP) is announcing the Spring meeting of the Federal Advisory Committee on Juvenile Justice (FACJJ), which will be held in Washington, DC March 16-17, 2009. Dates and Locations: The meeting times and locations are as follows: 1. Monday, March 16, 2009, 8 a.m. to 6 p.m., Office of Justice Programs, 810 Seventh Street, NW., Washington, DC 20531. (Open to Public) 2. Tuesday, March 17, 2009, 7:30 a.m. to 12 p.m., Oak Hill Youth Center Tour, Laurel, Maryland. (Closed Non-Deliberative Session.)
Schedules of Controlled Substances: Placement of Tapentadol Into Schedule II
Document Number: E9-3150
Type: Proposed Rule
Date: 2009-02-17
Agency: Drug Enforcement Administration, Department of Justice
This proposed rule is issued by the Deputy Administrator of the Drug Enforcement Administration (DEA) to place the substance tapentadol, including its isomers, esters, ethers, salts and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible, into schedule II of the Controlled Substances Act (CSA). This proposed action is based on a recommendation from the Assistant Secretary for Health of the Department of Health and Human Services (DHHS) and on an evaluation of the relevant data by DEA. If finalized, this action would impose the regulatory controls and criminal sanctions of schedule II on those who handle tapentadol and products containing tapentadol.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.